Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared
to moxifloxacin in the treatment of adults with community-acquired bacterial pneumonia.